Investment House LLC Sells 12,712 Shares of Solventum Corporation $SOLV

Investment House LLC lessened its stake in shares of Solventum Corporation (NYSE:SOLV) by 18.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 54,511 shares of the company’s stock after selling 12,712 shares during the quarter. Investment House LLC’s holdings in Solventum were worth $4,319,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Assetmark Inc. grew its stake in shares of Solventum by 21.4% during the fourth quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after buying an additional 128 shares during the last quarter. Hilltop National Bank lifted its holdings in shares of Solventum by 71.3% during the fourth quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the period. Allworth Financial LP lifted its holdings in shares of Solventum by 2.8% during the third quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC lifted its holdings in shares of Solventum by 0.5% during the third quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares during the period. Finally, BOKF NA lifted its holdings in shares of Solventum by 6.9% during the third quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares during the period.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Wedbush assumed coverage on shares of Solventum in a report on Friday, May 15th. They set an “outperform” rating and a $94.00 price target on the stock. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a report on Tuesday, January 27th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a report on Sunday, March 8th. Rothschild & Co Redburn assumed coverage on shares of Solventum in a report on Tuesday, March 24th. They set a “sell” rating and a $60.00 price target on the stock. Finally, Mizuho set a $100.00 price target on shares of Solventum and gave the stock an “outperform” rating in a report on Tuesday, January 20th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $84.25.

Solventum Price Performance

SOLV stock opened at $74.74 on Wednesday. The firm has a market cap of $12.94 billion, a price-to-earnings ratio of 9.16, a PEG ratio of 1.18 and a beta of 0.59. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20. The company’s fifty day simple moving average is $68.16 and its 200 day simple moving average is $74.65.

Solventum (NYSE:SOLV) last released its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.13. The business had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. Solventum had a net margin of 17.33% and a return on equity of 23.51%. Solventum’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, analysts expect that Solventum Corporation will post 6.57 earnings per share for the current year.

Insider Transactions at Solventum

In other news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction that occurred on Tuesday, March 10th. The shares were acquired at an average price of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the acquisition, the director directly owned 5,039 shares in the company, valued at approximately $342,803.17. This represents a 41.39% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.24% of the stock is currently owned by insiders.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.